Analyst Price Target is $12.50
▲ +209.41% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Portage Biotech in the last 3 months. The average price target is $12.50, with a high forecast of $12.50 and a low forecast of $12.50. The average price target represents a 209.41% upside from the last price of $4.04.
Current Consensus is
Reduce
The current consensus among 3 contributing investment analysts is to reduce stock in Portage Biotech. This rating changed within the last month from a Hold consensus rating.
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Read More
